Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has risen over 4%, currently trading at 5.66 HKD with a transaction volume of 14.93 million HKD, following the announcement of significant share purchases by CEO Dr. Yang Jianxin [1] Group 1: Share Purchase Details - On January 27, Basestone Pharmaceuticals announced that CEO Dr. Yang Jianxin purchased a total of 976,000 shares in the open market using personal funds between November 2025 and January 2026 [1] - Specifically, Dr. Yang acquired 428,500 shares on January 22 and January 23, 2026 [1] - Since taking on the role of CEO in August 2022, Dr. Yang has cumulatively purchased 12.477 million shares [1] Group 2: Ownership and Confidence - Following the recent share purchases, Dr. Yang holds approximately 4.87% of the company's total issued share capital as of the announcement date [1] - Dr. Yang expressed strong confidence in the company's long-term investment value and core competitive advantages, indicating belief in the company's ability to maintain stable operations and high-quality growth in the future [1] - He does not rule out the possibility of further increasing his shareholding at an appropriate time [1]
基石药业-B涨超4% 执行董事杨建新再度增持 累计买入近1248万股